Inivata receives accreditation from the College of American Pathologists (CAP)

2019, News

CAP Accreditation is Awarded to Clinical Laboratories Meeting the Highest Standards in Laboratory Practices.

Inivata, a leader in liquid biopsy, today announces that it has received Accreditation from the College of American Pathologists (CAP) for its CLIA laboratory in Research Triangle Park, North Carolina. The CAP Accreditation is awarded to laboratories which meet stringent quality, accuracy and consistency requirements.

The CAP Laboratory Accreditation Program began in the early 1960s and is widely recognized as being equal-to or more-stringent-than the US federal government’s inspection program instituted under the Clinical Laboratory Improvement Amendments of 1988 statute (CLIA). The Accreditation of the Inivata laboratory followed a recent site inspection, during which the laboratory records and quality control procedures for the previous two years were thoroughly examined.

 Dr Jamie Platt, Chief Operations Officer at Inivata, said: “At Inivata we are committed to delivering the highest quality information for clinicians and patients. Upholding stringent laboratory standards and a focused effort on continuous quality improvement are critical elements of our commitment. The CAP Accreditation demonstrates that our laboratory operates at the highest level, and supports us in delivering our mission to transform the lives of cancer patients through the power of liquid biopsy.”  

About the College of American Pathologists
As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.

More information about the CAP can be found at www.cap.org.

 

About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

 

Media Contacts

Consilium Strategic Communications

Chris Gardner/Angela Gray/Sarah Wilson

Paul Rabin (US)

inivata@consilium-comms.com +44 (0)20 3709 5700, +1 516 503 0271

 

Karen Chandler-Smith

karen.chandler-smith@inivata.com +44 (0)7900 430235

 

Our Technology

Our Solutions

Latest News